Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
about
Interpretation of the post-surgical Somatostatin Receptor Scintigram of a Primary Neuroendocrine Tumor of the Thymus: a case report and literature reviewTherapeutic radionuclides in nuclear medicine: current and future prospectsThe Beginning and Development of the Theranostic Approach in Nuclear Medicine, as Exemplified by the Radionuclide Pair 86Y and 90Y.The promise and pitfalls of positron emission tomography and single-photon emission computed tomography molecular imaging-guided radiation therapy.Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine - a reviewDosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review.Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors.Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray".Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors.Improving external beam radiotherapy by combination with internal irradiationRadioimmunoconjugates in acute leukemia treatment: the future is radiant.Three-dimensional radiobiological dosimetry of kidneys for treatment planning in peptide receptor radionuclide therapy.Pheochromocytoma and paraganglioma.203Pb-labeled alpha-melanocyte-stimulating hormone peptide as an imaging probe for melanoma detection.The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumoursPhase I trial of 90Y-DOTATOC therapy in children and young adults with refractory solid tumors that express somatostatin receptorsH(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapyH6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu.The production of [124I]iodine and [86Y]yttrium.Dosimetry of yttrium-labelled radiopharmaceuticals for internal therapy: 86Y or 90Y imaging?The rise of metal radionuclides in medical imaging: copper-64, zirconium-89 and yttrium-86.Patient-specific dosimetry in peptide receptor radionuclide therapy: a clinical review.Dual-Nuclide Radiopharmaceuticals for Positron Emission Tomography Based Dosimetry in Radiotherapy.Modular syntheses of H₄octapa and H₂dedpa, and yttrium coordination chemistry relevant to ⁸⁶Y/⁹⁰Y radiopharmaceuticals.alpha(v)beta(3) Integrin-targeting radionuclide therapy and imaging with monomeric RGD peptide.Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes.Quantitative Imaging for Targeted Radionuclide Therapy Dosimetry - Technical Review.Evaluation of sequential SPECT and CT for targeted radionuclide therapy dosimetry.Quantitative imaging of bromine-76 and yttrium-86 with PET: a method for the removal of spurious activity introduced by cascade gamma rays.Individualized dosimetry-based activity reduction of ⁹⁰Y-DOTATOC prevents severe and rapid kidney function deterioration from peptide receptor radionuclide therapy.The tumour sink effect on the biodistribution of 68Ga-DOTA-octreotate: implications for peptide receptor radionuclide therapy.
P2860
Q24795855-4654C6E2-00AD-4190-842D-0A157252A93AQ26861998-752C25FB-E893-4088-BB5E-E525DD4515FDQ33851546-720A5E17-7E04-4F91-BD66-5D33EF3F9807Q35111985-E56C7764-EA8F-4073-88E5-0274DD43E6E4Q35556123-F86FF374-62DC-49AC-9261-94B03E0B9C98Q35582104-59767814-B86E-46DA-B8A5-65322BBF0EF4Q35675435-75571D33-470C-44BD-8328-1BC5BF8F47A5Q35880923-525ED656-959F-44CC-A94B-DD22331126DEQ36008285-E6A90FCD-3291-4112-9A18-50FE9C384013Q36235732-C3BBEB8C-8DAA-4FE4-8CD6-5C2C78C94DF7Q36296126-1D79D616-684A-4FF8-A05B-9F568E4A1C21Q36300599-4F2F1EC2-78EC-4276-BE42-B122065AF113Q36467162-40414845-C44D-433B-A2B7-3E02C1F8F078Q36723832-1E11C0B2-1B14-4B87-8EB2-4D09E84D4DA3Q36755905-D170707C-68E5-4577-B07C-BB58A4A283DFQ37122608-44931810-BDC6-4ADA-9F26-1263F09CFDA7Q37209655-B97063C0-57DB-4BDB-A729-76CDB6F460DFQ37412579-B61156E5-1049-4CF1-85AC-A53AC57F1430Q37864154-0A155310-E9B1-48FE-80FB-951067C2A4C9Q37864161-9E3C3AA8-2E19-43D9-BA24-40CE48BD7024Q37869905-CB48D6DA-59E8-4B02-B66D-C475D3292D2DQ38271733-EF1A39D1-E7D4-42B5-B6FC-BDB31D6FB661Q38612027-47DAC1A3-7004-4877-8A37-BF0FD1D82AA4Q39221164-530FB46E-DFEC-417B-9D10-8BF2058E2117Q39979513-DE7935A3-B887-49E9-8461-180594057733Q40582226-4CB9E73F-5D8E-452F-AE6C-2DEFB81B35D2Q47124584-69A73C39-E4F4-4027-9AFD-AD7C8153587BQ47343725-632E3578-B348-41BF-A5AE-2FC591F10F03Q47583980-A4FF9A18-F9E4-41C0-82AD-492EB05B7EE8Q51242700-5B2815DB-FA5D-4684-B4F7-12B41394804DQ53201630-53508AD4-2187-4C80-B6DE-C7A27BE82350
P2860
Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
description
2001 nî lūn-bûn
@nan
2001 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Preliminary data on biodistrib ...... C and (111)In-DTPA-octreotide.
@ast
Preliminary data on biodistrib ...... C and (111)In-DTPA-octreotide.
@en
type
label
Preliminary data on biodistrib ...... C and (111)In-DTPA-octreotide.
@ast
Preliminary data on biodistrib ...... C and (111)In-DTPA-octreotide.
@en
prefLabel
Preliminary data on biodistrib ...... C and (111)In-DTPA-octreotide.
@ast
Preliminary data on biodistrib ...... C and (111)In-DTPA-octreotide.
@en
P2093
P356
P1476
Preliminary data on biodistrib ...... C and (111)In-DTPA-octreotide.
@en
P2093
Bartenstein PR
Brockmann JJ
Buchholz HG
Engelbach MJ
Förster GJ
P2888
P304
P356
10.1007/S002590100628
P577
2001-10-20T00:00:00Z